ES2181770T3 - Formulacion combinada farmaceutical para la contracepcion hormonal. - Google Patents

Formulacion combinada farmaceutical para la contracepcion hormonal.

Info

Publication number
ES2181770T3
ES2181770T3 ES95913171T ES95913171T ES2181770T3 ES 2181770 T3 ES2181770 T3 ES 2181770T3 ES 95913171 T ES95913171 T ES 95913171T ES 95913171 T ES95913171 T ES 95913171T ES 2181770 T3 ES2181770 T3 ES 2181770T3
Authority
ES
Spain
Prior art keywords
hormone
pct
preparation
estrogen
daily
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95913171T
Other languages
English (en)
Inventor
Ursula Lachnit
Bernd Dusterberg
Jurgen Spona
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6514578&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2181770(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering AG filed Critical Schering AG
Application granted granted Critical
Publication of ES2181770T3 publication Critical patent/ES2181770T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

LA PRESENTE INVENCION DESCRIBE UN PREPARADO COMBINADO FARMACEUTICO CON DOS COMPONENTES HORMONALES EN UNA UNIDAD DE ENVASADO SEPARADOS FISICAMENTE PARA LA ADMINISTRACION ORAL SECUENCIAL, QUE CONSISTE EN UNAS DOSIS DIARIAS QUE SE SACAN INDIVIDUALMENTE DE LA UNIDAD DE ENVASADO; CONTENIENDO EL PRIMERO DE LOS COMPONENTES COMO PRINCIPIO ACTIVO HORMONAL UNA DOSIS DE ESTROGENO COMBINADA CON UNA DOSIS DE UN PREPARADO DE GESTAGENO EN CANTIDAD SUFICIENTE PARA INHIBIR LA OVULACION, Y EL SEGUNDO COMPONENTE CONTIENE COMO PRINCIPIO ACTIVO HORMONAL SOLAMENTE UN PREPARADO DE ESTROGENO, COMPRENDIENDO EL PRIMER COMPONENTE 23 O 24 UNIDADES DIARIAS Y EL SEGUNDO DE 4 A 10 UNIDADES DIARIAS, Y SIENDO EL NUMERO TOTAL DE UNIDADES DIARIAS HORMONALES IGUAL AL NUMERO TOTAL DE DIAS DEL CICLO DESEADO, PERO AL MENOS DE 28 DIAS. ESTE PREPARADO COMBINADO, QUE SIRVE PARA EL CONTROL DE LA FERTILIDAD FEMENINA, PERMITE UN CONTENIDO LO MAS BAJO POSIBLE DE ESTROGENO EN CADA UNIDAD DE DOSIFICACION, Y TIENE TAMBIEN UN BAJO CONTENIDO TOTAL DE HORMONAS POR CICLO DE ADMINISTRACION, CON UNA ALTA SEGURIDAD CONTRACEPTIVA, BAJA INCIDENCIA EN EL DESARROLLO DE LOS FOLICULOS, LIBRE CONTROL DEL CICLO Y EVITANDO EL MANCHADO IRREGULAR Y EFECTOS NO DESEADOS.
ES95913171T 1994-03-30 1995-03-30 Formulacion combinada farmaceutical para la contracepcion hormonal. Expired - Lifetime ES2181770T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4411585A DE4411585A1 (de) 1994-03-30 1994-03-30 Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption

Publications (1)

Publication Number Publication Date
ES2181770T3 true ES2181770T3 (es) 2003-03-01

Family

ID=6514578

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95913171T Expired - Lifetime ES2181770T3 (es) 1994-03-30 1995-03-30 Formulacion combinada farmaceutical para la contracepcion hormonal.

Country Status (25)

Country Link
US (1) US5756490A (es)
EP (1) EP0750501B1 (es)
JP (1) JPH09511243A (es)
KR (1) KR100352571B1 (es)
CN (1) CN1108800C (es)
AT (1) ATE222494T1 (es)
AU (1) AU2073595A (es)
BG (1) BG63192B1 (es)
BR (1) BR9507251A (es)
CA (1) CA2186739A1 (es)
CZ (1) CZ291698B6 (es)
DE (2) DE4411585A1 (es)
DK (1) DK0750501T3 (es)
ES (1) ES2181770T3 (es)
FI (1) FI963831A (es)
HU (1) HUT75521A (es)
NO (1) NO964089L (es)
NZ (1) NZ282824A (es)
PL (1) PL316569A1 (es)
PT (1) PT750501E (es)
RO (1) RO118375B1 (es)
RU (1) RU2165258C2 (es)
SK (1) SK124396A3 (es)
UA (1) UA41401C2 (es)
WO (1) WO1995026730A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4344462C2 (de) 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
EP0792152B1 (en) * 1994-11-22 2004-04-14 Balance Pharmaceuticals, Inc. Methods of contraception
DE19513662A1 (de) * 1995-04-08 1996-10-10 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
DE19525017A1 (de) * 1995-06-28 1997-01-02 Schering Ag Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption
AU726283B2 (en) * 1995-06-28 2000-11-02 Schering Aktiengesellschaft Pharmaceutical combined preparations, kit and method for hormonal contraception
US5747480A (en) * 1996-05-08 1998-05-05 American Home Products Corporation Oral contraceptive
WO1997041868A1 (en) * 1996-05-08 1997-11-13 American Home Products Corporation Oral contraceptive
ES2229378T3 (es) * 1996-07-26 2005-04-16 Wyeth Anticonceptivo oral.
US6451778B1 (en) 1996-07-26 2002-09-17 Wyeth Oral contraceptive
WO1998004267A1 (en) * 1996-07-26 1998-02-05 American Home Products Corporation Progestin/estrogen oral contraceptive
JP2000515890A (ja) * 1996-07-26 2000-11-28 アメリカン・ホーム・プロダクツ・コーポレイション プロゲスチンとエストロゲンとの混合剤からなる一相性避妊法およびキット
US5888543A (en) * 1996-07-26 1999-03-30 American Home Products Corporation Oral contraceptives
US6479475B1 (en) 1996-07-26 2002-11-12 Wyeth Oral contraceptive
US5858405A (en) * 1996-07-26 1999-01-12 American Home Products Corporation Oral contraceptive
US5898032A (en) * 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
DK1598069T3 (da) * 1999-08-31 2009-07-06 Bayer Schering Pharma Ag Farmaceutisk præparat af ethinylestradiol og drospirenon til anvendelse som præventionsmiddel
CA2382426C (en) * 1999-08-31 2006-02-28 Schering Aktiengesellschaft Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
EP2305267A3 (en) 1999-08-31 2011-08-17 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
US6787531B1 (en) 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
PT1453521E (pt) 2001-12-05 2013-10-08 Teva Womens Health Inc Contracetivos orais para prevenir a gravidez e diminuir a sintomatologia pré-menstrual
CA2771944A1 (en) * 2003-07-16 2005-01-27 Teva Women's Health, Inc. Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
WO2005032558A1 (en) * 2003-10-01 2005-04-14 Janssen Pharmaceutica N.V. Extended triphasic contraceptive regimens
US20050113350A1 (en) * 2003-11-26 2005-05-26 Bernd Duesterberg Extended use combination comprising estrogens and progestins
EP1535618A1 (en) * 2003-11-26 2005-06-01 Schering Aktiengesellschaft Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions
US20070111975A1 (en) 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
US7704984B2 (en) * 2005-04-22 2010-04-27 Warner Chilcott Company, Llc Extended estrogen dosing contraceptive regimen
SG172654A1 (en) * 2006-03-02 2011-07-28 Warner Chilcott Co Llc Extended cycle multiphasic oral contraceptive method
US11376263B2 (en) 2020-10-08 2022-07-05 Fortress Biotech, Inc. Cyproterone acetate compositions and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6615481A (es) * 1966-11-02 1968-05-03
US3639600A (en) * 1969-08-28 1972-02-01 Upjohn Co Process of establishing cyclicity in a human female
US4921843A (en) * 1988-10-20 1990-05-01 Pasquale Samuel A Contraception system and method
IE71203B1 (en) * 1990-12-13 1997-02-12 Akzo Nv Low estrogen oral contraceptives
DE4104385C1 (es) * 1991-02-09 1992-08-13 Marika Dr.Med. 6509 Framersheim De Ehrlich

Also Published As

Publication number Publication date
KR100352571B1 (ko) 2003-01-06
DE4411585A1 (de) 1995-10-05
NZ282824A (en) 1998-07-28
BG100940A (en) 1998-03-31
DE59510333D1 (de) 2002-09-26
NO964089D0 (no) 1996-09-27
BR9507251A (pt) 1997-09-02
MX9604440A (es) 1997-07-31
BG63192B1 (bg) 2001-06-29
DK0750501T3 (da) 2002-12-23
NO964089L (no) 1996-11-07
HUT75521A (en) 1997-05-28
RO118375B1 (ro) 2003-05-30
RU2165258C2 (ru) 2001-04-20
EP0750501A1 (de) 1997-01-02
CN1159161A (zh) 1997-09-10
US5756490A (en) 1998-05-26
ATE222494T1 (de) 2002-09-15
CN1108800C (zh) 2003-05-21
EP0750501B1 (de) 2002-08-21
PL316569A1 (en) 1997-01-20
FI963831A0 (fi) 1996-09-25
HU9602657D0 (en) 1996-11-28
FI963831A (fi) 1996-11-29
UA41401C2 (uk) 2001-09-17
CZ287996A3 (en) 1997-02-12
PT750501E (pt) 2003-01-31
CA2186739A1 (en) 1995-10-12
CZ291698B6 (cs) 2003-05-14
WO1995026730A1 (de) 1995-10-12
AU2073595A (en) 1995-10-23
JPH09511243A (ja) 1997-11-11
SK124396A3 (en) 1997-05-07

Similar Documents

Publication Publication Date Title
ES2181770T3 (es) Formulacion combinada farmaceutical para la contracepcion hormonal.
PT835114E (pt) Preparado de combinacao farmaceutico kit e metodo para contracepcao hormonal
ES2086644T3 (es) Preparado anovulatorio para la contracepcion hormonal.
JPH1129481A (ja) 月経の出血を少なくし維持された効力を持つ超低投与量避妊薬
KR900701277A (ko) 피임 시스템 및 방법
KR20150058555A (ko) 연장된 호르몬성 피임제 투약법에서 파탄성 출혈의 관리
NO974630L (no) Farmasöytisk kombinasjonspreparat for hormonell antikonsepsjon